Share ownership Jazz Pharmaceuticals plc

JAZZ

IE00B4Q5ZN47

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-04 pm EST			5-day change	1st Jan Change
166.91 ^USD	-0.11%		-5.66%	+35.53%

Dec. 02	Jazz Pharmaceuticals plc to Present Pivotal Phase 3 Results of Ziihera®? (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCOGastrointestinal Cancers Symposium	CI
Dec. 02	Jazz Pharmaceuticals plc Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 09:45 AM

Share class: Jazz Pharmaceuticals plc

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	60,454,592	58,676,006 ( 97.06 %)	0	97.06 %

Major shareholders: Jazz Pharmaceuticals plc

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 9.738 %	5,906,945	9.738 %	813 M $
BlackRock Advisors LLC 8.617 %	5,226,841	8.617 %	719 M $
DFA Australia Ltd. 4.494 %	2,725,793	4.494 %	375 M $
Capital Research & Management Co. (World Investors) 4.212 %	2,554,867	4.212 %	352 M $
LSV Asset Management 4.141 %	2,511,858	4.141 %	346 M $
STATE STREET CORPORATION 3.079 %	1,867,886	3.079 %	257 M $
JPMorgan Investment Management, Inc. 3.078 %	1,867,159	3.078 %	257 M $
Ameriprise Financial Services LLC 3.046 %	1,847,455	3.046 %	254 M $
EcoR1 Capital, LLC 2.813 %	1,706,469	2.813 %	235 M $
Fuller & Thaler Asset Management, Inc. 2.681 %	1,626,136	2.681 %	224 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	88.89%
Other	7%
Individuals	3.59%
State Street Corp.	3.08%
Swedbank AB	1.77%
Manulife Financial Corp.	0.85%
Schweizerische Nationalbank	0.18%
SEI Investments Co.	0.18%
Governments	0.13%
MidWestOne Financial Group, Inc.	0.06%
Hancock Whitney Corp.	0.01%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	85.44%
Australia	4.58%
United Kingdom	4.04%
Individuals	3.59%
Canada	2.34%
Sweden	1.93%
France	1.06%
Switzerland	0.66%
Belgium	0.41%
Germany	0.31%
Ireland	0.26%
Norway	0.22%
Luxembourg	0.21%
Denmark	0.19%
Netherlands	0.17%
Finland	0.09%
Taiwan	0.06%
Italy	0.05%
Hong Kong	0.03%
Puerto Rico	0.02%
China	0.02%
Austria	0.02%
Spain	0.02%
New Zealand	0.01%
Slovenia	0.01%

Based on 1000 largest holdings

Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Companyâs lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).

Employees

2,800

Sector

Pharmaceuticals

Calendar

Jan. 08 - American Society of Clinical Oncology Gastrointestinal Cancers Symposium - Abstract # LBA285

More about the company